Patients, n | 362 | 56 |
Median age (range), years | 61.8 (28–89) | 59.5 (28–89) |
Female | 213 (58.8) | 33 (58.9) |
Never-smokers | 257 (71.0) | 40 (71.4) |
ECOG 0–1 | 332 (91.7) | 53 (94.6) |
Co-existence with other malignancies | 22 (6.1) | 1 (1.8) |
Tumour relapse (previous stage ≤IIIA) | 70 (19.3) | 12 (23.2) |
Metastatic sites | | |
Bone | 145 (40.1) | 20 (35.7) |
Lung | 144 (39.8) | 17 (30.4) |
Brain | 110 (30.4) | 16 (28.6) |
Pleural seeding or effusion | 101 (27.9) | 15 (26.8) |
Liver | 26 (7.2) | 2 (3.6) |
Adrenal gland | 16 (4.4) | 3 (5.4) |
EGFR mutation type | | |
Common mutations | 281 (77.6) | 42 (75.0) |
Exon 19 deletion | 194 (53.6) | 26 (46.4) |
p.L858R | 85 (23.5) | 16 (28.6) |
p.L858R+exon 19 deletion | 3 (0.8) | 0 |
Common/uncommon mutations | 16 (4.4) | 4 (7.1) |
Uncommon mutations | 65 (18.0) | 10 (17.9) |
Tumour response to afatinib | | |
Partial response: | 265 (73.2) | 44 (78.6) |
for common mutations | 217/281 (77.2) | 35/42 (83.3) |
for common/uncommon mutations | 11/16 (68.8) | 3/4 (75.0) |
for uncommon mutations | 37/65 (56.9) | 6/10 (60.0) |
Stable disease | 64 (17.7) | 10 (17.9) |
Progressive disease | 33 (9.1) | 2(3.6) |